Pharmaceutical firm Phapros, subsidiary of state-owned trading firm Rajawali Nusantara (RNI), performed better compared to state-owned Indofarma (INAF). In the first half (H1) of 2018, Phapros reported a 45,8% jump in net profit to Rp53 billion, while INAF only booked a net profit of Rp253 million, but significantly improved from loss Rp53.54 billion in H1 of last year.

To subscribe please click here